Physician profile
Whitney Bolton Erickson
NPI 1578995791
$158,964.84
in general payments reported to CMS, 2019-2025
29 companies · $71K in 2025
The $71K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,898 · 2022: $14K · 2023: $28K · 2024: $44K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Consulting Fee: $18K · Travel and Lodging: $13K · Food and Beverage: $11K · Honoraria: $5,769 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,932.50 |
| Consulting Fee | $18,030.50 |
| Travel and Lodging | $12,539.10 |
| Food and Beverage | $11,147.72 |
| Honoraria | $5,769.00 |
| Education | $179.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101,535.60 | 2021-2025 | Caplyta |
| Abbvie INC. | $27,423.52 | 2021-2025 | |
| Axsome Therapeutics, INC. | $23,582.95 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $2,191.00 | 2021-2025 | Spravato, Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $875.48 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $426.81 | 2021-2025 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $321.78 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $293.20 | 2021-2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $259.16 | 2021-2025 | Aplenzin |
| Lundbeck LLC | $245.03 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $213.23 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Sunovion Pharmaceuticals INC. | $186.44 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $178.49 | 2021-2025 | Ingrezza |
| Lilly USA, LLC | $171.31 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $147.87 | 2022-2025 | Azstarys |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $144.08 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $118.04 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.83 | 2024 | |
| Almatica Pharma LLC | $80.03 | 2021 | |
| Tris Pharma INC | $79.76 | 2022-2024 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $53.04 | 2022 | |
| Collegium Pharmaceutical, INC. | $42.14 | 2025 | Jornay Pm |
| Novo Nordisk INC | $41.33 | 2022-2023 | Wegovy |
| Ironshore Pharmaceuticals INC. | $33.87 | 2021-2023 | Jornay Pm |
| Sage Therapeutics, LLC | $33.50 | 2023 | |
| Eisai INC. | $32.91 | 2021 | |
| Adlon Therapeutics L.P. | $21.84 | 2021 | |
| Owp Pharmaceuticals, INC. | $18.60 | 2023 | Subvenite, Lamotrigine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.